UBS Group’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,398
| Closed | -$70 | – | 9331 |
|
|
2024
Q3 | $70 | Buy |
5,398
+1,497
| +38% | +$19 | ﹤0.01% | 7982 |
|
|
2024
Q2 | $109 | Buy |
3,901
+3,768
| +2,833% | +$105 | ﹤0.01% | 7986 |
|
|
2024
Q1 | $7 | Buy |
+133
| New | +$7 | ﹤0.01% | 7957 |
|
|
2023
Q4 | – | Sell |
-80
| Closed | -$18 | – | 8783 |
|
|
2023
Q3 | $18 | Sell |
80
-2,709
| -97% | -$610 | ﹤0.01% | 7993 |
|
|
2023
Q2 | $318 | Sell |
2,789
-310
| -10% | -$35 | ﹤0.01% | 7227 |
|
|
2023
Q1 | $124 | Sell |
3,099
-1,901
| -38% | -$76 | ﹤0.01% | 8102 |
|
|
2022
Q4 | $150 | Buy |
5,000
+3,425
| +217% | +$103 | ﹤0.01% | 9150 |
|
|
2022
Q3 | $0 | Hold |
1,575
| – | – | ﹤0.01% | 9875 |
|
|
2022
Q2 | $0 | Buy |
1,575
+300
| +24% | – | ﹤0.01% | 9912 |
|
|
2022
Q1 | $0 | Buy |
1,275
+100
| +9% | – | ﹤0.01% | 9760 |
|
|
2021
Q4 | $1K | Buy |
+1,175
| New | +$1K | ﹤0.01% | 8928 |
|